Cliff Asness AQR Capital Management
Cliff Asness is a co-founder of AQR Capital Management, a leading quantitative investment firm spanning equities, alternatives, and factor strategies. He is known for academic-informed research on value, momentum, and other systematic premia, as well as candid market commentary. Asness’s work bridges academic finance and large-scale institutional portfolio management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$234M |
| 2 |
eBay
EBAY
|
+$223M |
| 3 |
Walt Disney
DIS
|
+$189M |
| 4 |
Humana
HUM
|
+$184M |
| 5 |
DXC Technology
DXC
|
+$172M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wells Fargo
WFC
|
+$236M |
| 2 |
Citizens Financial Group
CFG
|
+$157M |
| 3 |
Applied Materials
AMAT
|
+$156M |
| 4 |
Huntsman Corp
HUN
|
+$154M |
| 5 |
STI
SunTrust Banks, Inc.
STI
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.97% |
| 2 | Technology | 16.56% |
| 3 | Industrials | 15.08% |
| 4 | Healthcare | 12.53% |
| 5 | Consumer Discretionary | 12.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MCF
1251
DELISTED
Contango Oil & Gas Co.
MCF
| $2.83M | ﹤0.01% |
426,112
-114,766
| -21% | -$801K |
|
|
BPMC
1252
DELISTED
Blueprint Medicines
BPMC
| $2.82M | ﹤0.01% |
55,595
+31,534
| +131% | +$1.34M |
|
1253
NMI Holdings
NMIH
$3.42B
| $2.81M | ﹤0.01% |
245,805
-15,159
| -6% | -$170K |
|
1254
BorgWarner
BWA
$13.1B
| $2.81M | ﹤0.01% |
+75,374
| New | +$2.73M |
|
1255
MGP Ingredients
MGPI
$384M
| $2.79M | ﹤0.01% |
54,427
+137
| +0.3% | +$7.15K |
|
|
PACW
1256
DELISTED
PacWest Bancorp
PACW
| $2.79M | ﹤0.01% |
59,629
+23,649
| +66% | +$1.15M |
|
1257
LKQ Corp
LKQ
$6.51B
| $2.78M | ﹤0.01% |
84,335
-4,186
| -5% | -$129K |
|
1258
Regeneron Pharmaceuticals
REGN
$85.3B
| $2.76M | ﹤0.01% |
5,624
-3,181
| -36% | -$1.39M |
|
1259
Innoviva
INVA
$1.52B
| $2.76M | ﹤0.01% |
+215,715
| New | +$2.71M |
|
1260
MaxLinear
MXL
$5.69B
| $2.76M | ﹤0.01% |
98,899
-40,178
| -29% | -$1.17M |
|
1261
Coeur Mining
CDE
$21.5B
| $2.74M | ﹤0.01% |
319,426
-79,565
| -20% | -$723K |
|
|
BEAT
1262
DELISTED
BioTelemetry, Inc.
BEAT
| $2.73M | ﹤0.01% |
81,626
-29,874
| -27% | -$891K |
|
1263
TC Energy
TRP
$64.7B
| $2.72M | ﹤0.01% |
57,136
-106,170
| -65% | -$4.99M |
|
1264
Pathward Financial
CASH
$1.72B
| $2.72M | ﹤0.01% |
91,554
-7,392
| -7% | -$215K |
|
1265
Brady Corp
BRC
$4.45B
| $2.71M | ﹤0.01% |
80,019
-109,313
| -58% | -$4.07M |
|
|
WLB
1266
DELISTED
Westmoreland Coal Company
WLB
| $2.71M | ﹤0.01% |
556,307
+67,411
| +14% | +$590K |
|
|
RP
1267
DELISTED
RealPage, Inc.
RP
| $2.69M | ﹤0.01% |
74,977
+1,425
| +2% | +$50.9K |
|
|
EXTN
1268
DELISTED
Exterran Corporation
EXTN
| $2.68M | ﹤0.01% |
100,534
-193,713
| -66% | -$5.5M |
|
1269
HealthEquity
HQY
$8.81B
| $2.68M | ﹤0.01% |
53,734
+556
| +1% | +$26K |
|
|
POLY
1270
DELISTED
Plantronics, Inc.
POLY
| $2.67M | ﹤0.01% |
51,025
-76,925
| -60% | -$4.14M |
|
|
ARRY
1271
DELISTED
Array Biopharma Inc
ARRY
| $2.67M | ﹤0.01% |
318,666
+976
| +0.3% | +$7.98K |
|
1272
Tronox
TROX
$861M
| $2.67M | ﹤0.01% |
176,288
+110,278
| +167% | +$1.77M |
|
|
UFS
1273
DELISTED
DOMTAR CORPORATION (New)
UFS
| $2.67M | ﹤0.01% |
69,353
-80,416
| -54% | -$3.01M |
|
|
CCRN
1274
DELISTED
Cross Country Healthcare
CCRN
| $2.66M | ﹤0.01% |
205,831
+130,553
| +173% | +$1.68M |
|
1275
Gildan
GIL
$10.2B
| $2.66M | ﹤0.01% |
86,580
+16,951
| +24% | +$487K |
|
Similar funds
Cliff Asness's Q2 2017 Portfolio in Review
As of Q2 2017, Cliff Asness held 2,306 positions worth $75.6B, up 0.44% from $75.2B the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
Cliff Asness's Q2 2017 filing shows 139 new, 928 increased, 1,013 reduced and 118 closed positions. Its largest new stake was DXC Technology: 2,594,054 shares worth $172M. The largest sale was Wells Fargo, an estimated $236M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, down from 18% a quarter earlier, followed by Technology and Industrials.
- Cliff Asness's largest Q2 2017 buy was DXC Technology: 2,594,054 shares worth $172M.
- Cliff Asness added most to Gilead Sciences in Q2 2017, an estimated $234M increase.
- Cliff Asness's biggest Q2 2017 reduction was Wells Fargo, cutting an estimated $236M.
- Cliff Asness fully exited Computer Sciences in Q2 2017, selling an estimated $77.8M.
- Cliff Asness's ten largest holdings make up 9.2% of its $75.6B portfolio in Q2 2017.
- Cliff Asness opened 139 new positions and closed 118 in Q2 2017.
- Cliff Asness's portfolio value rose 0.44% quarter-over-quarter to $75.6B.
Based on AQR Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.